GT4 prevalence in the US is de minimis; in Europe, on the other hand, GT4 is a significant market, which is why Viekira Pak will be approved by the EMA as two products rather than one. I.e., EU patients with GT4 will be able to omit Exviera (ABT-333).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.